# Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Source: https://onco.cc/trials/nct04736589/  
OnCo record `nct04736589` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Inetetamab, Sirolimus protein-bound particles and Pyrotinib in Breast cancer, run by Peking Union Medical College, not yet recruiting.

## Summary

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway is a phase 3 interventional study registered as NCT04736589 by Peking Union Medical College, with 270 participants planned, started 2021-02-02 and due to reach its primary completion in 2024-02-02. Interventions recorded: Inetetamab, Rapamycin, Pyrotinib, Chemotherapy. Conditions recorded: Breast Cancer.

Linked to the drug Inetetamab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04736589
- Phase: 3
- Setting: Efficacy and Safety of Inetetamab Combined With Rapamycin and Chemotherapy for HER2-positive Metastatic Breast Cancer Patients With Abnormal Activation of PI3K/Akt/mTOR Pathway After Progression on Trastuzumab.
- Sponsor: Peking Union Medical College
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT04736589: https://clinicaltrials.gov/study/NCT04736589

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Inetetamab](https://onco.cc/drugs/inetetamab/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Sirolimus protein-bound particles](https://onco.cc/drugs/sirolimus-albumin-bound/)

---
JSON: https://onco.cc/api/v1/entities/nct04736589.json